radiation therapy | Biomarker Commons

radiation therapy

CvergenX, Inc. Partners with National Cancer Institute to Develop New Test to Predict Radiation Therapy Success

A molecular signature index technology that can lead to better radiation therapy decisions for patients with cancer is being developed into a reliable radiosensitivity test by CvergenX, Inc., an advanced cancer diagnostics company. It is being done in conjunction with the National Cancer Institute’s Clinical Assay Development Program (CADP).


Premium Subscription Required for Access


Premium Subscription Required for Access


Premium Subscription Required for Access


Premium Subscription Required for Access